Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - TD Cowen raised its price target on Supernus Pharmaceuticals (NASDAQ:SUPN) to $60.00 from $45.00 on Thursday, while maintaining a Buy rating on the stock. The company, currently trading at $50.67 with a market cap of $2.84 billion, has shown impressive momentum with a 63% gain over the past six months. According to InvestingPro, the company maintains a "GREAT" financial health score.
The firm cited stronger-than-expected adoption of Onapgo, with projected sales of $8 million in the third quarter and $23 million for 2025, which TD Cowen noted "could be potentially conservative."
Qelbree, another drug in the Supernus portfolio, is also showing strong market performance, prompting TD Cowen to increase its 2025 sales estimate for the medication to $310 million.
The research firm also mentioned Zurzuvae as an additional product expected to contribute to the company’s "solid ongoing launches."
TD Cowen’s new $60 price target is derived from a discounted cash flow (DCF) analysis and represents significant upside potential for the pharmaceutical company’s shares.
In other recent news, Supernus Pharmaceuticals has been the subject of several analyst assessments and updates. Piper Sandler upgraded the company from Neutral to Overweight, raising its price target to $65.00, driven by the sales potential of Onapgo, an apomorphine-based infusion pump for Parkinson’s disease. Cantor Fitzgerald also increased its price target to $63.00, citing a faster-than-anticipated adoption rate of Onapgo, which led to higher peak sales estimates. Stifel raised its price target to $43.00 following Supernus’s strong second-quarter 2025 performance, where revenues reached $165.5 million, surpassing the consensus estimate of $154.1 million. The revenue growth was largely attributed to the success of the company’s Qelbree and Gocovri products. Piper Sandler had previously raised its price target to $40.00, highlighting the positive launch performance of Onapgo. These developments reflect a positive outlook from analysts, with several firms adjusting their projections based on the company’s recent performance and product launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.